FLINT, Mich.— Nov. 07, 2013 —On Monday, October 21, 2013, the U.S. Food and Drug Administration approved a subcutaneous formulation of Actemra® (tocilizumab).  This new product was approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs).  Methotrexate is an example of a DMARD.  Tocilizumab may be used alone or as a component of a combination therapy regimen consisting of methotrexate or other non-biologic DMARDs.  The subcutaneous product will be available as 162 mg single-use prefilled syringes.  The product is expected to be available in November 2013.

Actemra® was previously approved as an intravenous (IV) infusion for the treatment of RA, polyarticular juvenile idiopathic arthritis (PJIA), and systemic juvenile idiopathic arthritis (SJIA).  Diplomat will be able to distribute this medication when it is available.

For more information about our support services for patients with rheumatoid arthritis, visit our website. You may also contact us directly at 877.977.9118 or, if your inquiry is not urgent, email us at dspinfo@diplomatpharmacy.com.